Auteur B. PULVER

  Tris disponibles Ajouter le résultat à votre sélection

  Affiner la recherche

EMCDDA framework and practical guidance for naming cathinones

B. PULVER ; S. FISCHMANN ; A. GALLEGOS ; R. CHRISTIE | 2024
Dans Drug Testing and Analysis (Vol.16, n°12, December 2024) Article : Périodique

Cathinones are often sold as "legal" alternatives to controlled stimulants such as amphetamine, MDMA and cocaine. Cathinones are the second largest group of new psychoactive substances (NPS), with close to 170 monitored by the European Monitorin[...]

Plus d'info

Ajouter à la sélection

Lien externe

EMCDDA framework and practical guidance for naming synthetic cannabinoids

B. PULVER ; S. FISCHMANN ; A. GALLEGOS ; R. CHRISTIE | 2023
Dans Drug Testing and Analysis (Vol.15, n°3, March 2023) Article : Périodique

Synthetic cannabinoids (SCs), often sold as "legal" replacements for cannabis, are the largest group of new psychoactive substances monitored by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Currently, close to 240 struct[...]

Plus d'info

Ajouter à la sélection

Lien externe

Human phase-I metabolism of three synthetic cannabinoids bearing a cumyl moiety and a cyclobutyl methyl or norbornyl methyl tail: Cumyl-CBMEGACLONE, Cumyl-NBMEGACLONE, and Cumyl-NBMINACA

A. GIORGETTI ; P. BRUNETTI ; B. HASCHIMI ; B. PULVER ; J. P. PASCALI ; J. RIEDEL ; V. AUWARTER | 2025
Dans Drug Testing and Analysis (Vol.17, n°6, June 2025) Article : Périodique

Synthetic cannabinoid receptor agonists (SCRAs) continue to show high prevalence on the new psychoactive substances drug market. Around 2019-2020, new SCRAs bearing a cumyl moiety emerged: Cumyl-CBMEGACLONE and Cumyl-NBMEGACLONE, carrying a cycl[...]

Plus d'info

Ajouter à la sélection

Lien externe